ArticlePloS one2013
Prevalence of symptomatic heart failure with reduced and with normal ejection fraction in an elderly general population-the CARLA study.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- Pharmacokinetic Alterations in Patients with Chronic Heart Failure: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Real-World Association of SGLT2 Inhibitors with Mortality in Very Elderly Patients with HFrEF and CKD.Biomedicines · 2026Article
- Physician adherence to heart failure with reduced ejection fraction treatment guidelines: a cross-sectional study in Northwest Ethiopia.BMC cardiovascular disorders · 2025Article
- Rehospitalisation rates of heart failure patients treated with SGLT2 inhibitors as an inpatient versus post-discharge.The British journal of cardiology · 2024Article
- The Prevalence and Risk Factors of Chronic Heart Failure in the Mongolian Population.Diagnostics (Basel, Switzerland) · 2023Article
- Prevalence, Characteristics, Management and Outcomes of Patients with Heart Failure with Preserved, Mildly Reduced, and Reduced Ejection Fraction in Spain.Journal of clinical medicine · 2022Article
- Cardiovascular risk factors, living and ageing in Halle: the CARLA study.European journal of epidemiology · 2022Article
- Prevalence of Chronic Heart Failure, Associated Factors, and Therapeutic Management in Primary Care Patients in Spain, IBERICAN Study.Journal of clinical medicine · 2021Article
- Patients with Heart Failure During and After Inpatient Cardiac Rehabilitation.Vascular health and risk management · 2021Article
- Eligibility for dapagliflozin in unselected patients hospitalised with decompensated heart failure.The British journal of cardiology · 2021Article
- The ventilatory abnormalities and prognostic values of HESC heart failure · 2020Article
- Early Detection of Heart Failure With Reduced Ejection Fraction Using Perioperative Data Among Noncardiac Surgical Patients: A Machine-Learning Approach.Anesthesia and analgesia · 2020Observational
- Comparing inpatient costs of heart failure admissions for patients with reduced and preserved ejection fraction with or without type 2 diabetes.Cardiovascular endocrinology & metabolism · 2020Article
- Article
- Retropharyngeal hematoma in the context of obstructive sleep apnea: a case report and review of the literature.Journal of medical case reports · 2019Review
- Demographics of patients with heart failure who were over 80 years old and were admitted to the cardiology clinics in Turkey.Anatolian journal of cardiology · 2019Article
- Left atrial function in heart failure with mid-range ejection fraction differs from that of heart failure with preserved ejection fraction: a 2D speckle-tracking echocardiographic study.European heart journal. Cardiovascular Imaging · 2019Article
- Article
- Chronic heart failure management in primary healthcare in Poland: Results of a nationwide cross-sectional study.The European journal of general practice · 2018Article
- Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany.PharmacoEconomics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesChronic heart failure (CHF) is one of the most important public health concerns in the industrialized world having increasing incidence and prevalence. Although there are several studies describing the prevalence of heart failure with reduced ejection fraction (HFREF) and heart failure with normal ejection fraction (HFNEF) in selected populations, there are few data regarding the prevalence and the determinants of symptomatic heart failure in the general population.
methodsCross-sectional data of a population-based German sample (1,779 subjects aged 45-83 years) were analyzed to determine the prevalence and determinants of chronic SHF and HFNEF defined according to the European Society of Cardiology using symptoms, echocardiography and serum NT-proBNP. Prevalence was age-standardized to the German population as of December 31st, 2005.
resultsThe overall age-standardized prevalence of symptomatic CHF was 7.7% (95%CI 6.0-9.8) for men and 9.0% (95%CI 7.0-11.5) for women. The prevalence of CHF strongly increased with age from 3.0% among 45-54- year-old subjects to 22.0% among 75-83- year-old subjects. Symptomatic HFREF could be shown in 48% (n = 78), symptomatic HFNEF in 52% (n = 85) of subjects with CHF. The age-standardized prevalence of HFREF was 3.8 % (95%CI 2.4-5.8) for women and 4.6 % (95%CI 3.6-6.3) for men. The age-standardized prevalence of HFNEF for women and men was 5.1 % (95%CI 3.8-7.0) and 3.0 % (95%CI 2.1-4.5), respectively. Persons with CHF were more likely to have hypertension (PR = 3.4; 95%CI 1.6-7.3) or to have had a previous myocardial infarction (PR = 2.5, 95%CI 1.8-3.5).
conclusionThe prevalence of symptomatic CHF appears high in this population compared with other studies. While more women were affected by HFNEF than men, more male subjects suffered from HFREF. The high prevalence of symptomatic CHF seems likely to be mainly due to the high prevalence of cardiovascular risk factors in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.